Last but not least, our data demonstrated the potential of VSTM2A in immune regulation in KO mouse and human PBMC models; however, due to a lack of clinical specimens, we were unable to evaluate the VSTM2A expression and efficacy and prognosis of existing ICI-related therapies in patients with CRC. The gene discussed is VSTM2A; the disease is colorectal carcinoma.